In the 1990s, the DNA alkylating agent temozolomide was tested and approved by the FDA as a chemotherapeutic agent for the treatment of malignant glioma. Addition of temozolomide to surgical resection and radiotherapy extends median survival to 14.6 months and the 2-year survival rate to 27% compa...
survival ratediagnosisGliomas are the most common primary malignant brain tumor in the United States with previous studies showing the incidence varied by age, sex, and race or ethnicity. Survival after diagnosis has also been shown to vary by these factors. Also, socioeconomic status and its ...
The RTK-PI3K-AKT-mTOR signaling pathway is central to regulating tumor growth by controlling cell survival, proliferation, protein translation, and motility [171,172]. This pathway is activated in most glioma patients and is influenced by several alterations, such as Phosphatase and Tensin Homolog (...
To evaluate the NDMI score as a prognostic marker in glioma, we entered patients’ NDMI scores into a survival elastic net model that included conventional risk factors of age, gender, tumor classification, tumor location, surgery and chemoradiation treatments, and DEX use at blood draw as well ...
Glioblastoma is the highest-grade, most malignant form of astrocytoma, and it is the most common and aggressive type of human brain tumor, with a 5-year survival rate of only 5% [201]. While not all gliomas may be neural crest-derived, since NCC do give rise to certain populations of ...
a general-purpose surgical adjunct, FastGlioma provides physicians with real-time, accurate and clinically actionable diagnostic information within seconds of tissue biopsy that can improve the surgical care of patients with brain tumours, thereby increasing patient quality of life and overall survival. ...
and many options have become available to minimize adverse effects and improve survival rates and quality of life. Proton therapy (PT), or proton beam radiation therapy (PBRT), offers certain advantages to other modern photon-based conformal therapy when used in the treatment of CNS malignancies ...
ALKBH5 may serve as an important indicator to predict the prognosis of GBM patients, with a low expression of ALKBH5 being closely associated with prolonged overall survival. MiR-193a-3p, a tumor suppressor, targets ALKBH5 exerting an anti-tumor effect by restraining the growth of glioma cells...
Glioma myeloid cell-type composition associates with patient genotype, overall survival and response to anti-PD-1 therapy. A-G UMAP plots showing selected cells by SCISSOR analysis. Dots are colored according to the association of cells with the phenotype (blue: negative, red: positive). Shown ...
For instance, IDH mutant (IDHmut) gliomas with 1p/19q codeletion often signal a better prognosis [11, 12], and the co-occurrence of IDH and TERT promoter muta- tions in oligodendrogliomas correlates with an improved survival rate, unlike the prognosis for tumors with TERT mutations (TERTmut...